R&D Changing Faces: Pharma and biotech, April 2026 April didn’t see too much activity at the big pharmas, but saw plenty of executive movement at small and midsized biotechs.
R&D Why UCB bet a billion dollars on cell therapy for epilepsy UCB's chief science officer spoke to pharmaphorum about why Neurona's in-development cell therapy could be a game changer for epilepsy treatment.
R&D Bridging ethics and efficacy in IRB review of vaccine trials Institutional Review Boards (IRBs) play a key role in evaluating scientific integrity and participant safety.
R&D A patient-first mindset for change May marks World Clinical Trials Day, bringing awareness to trials and the vital role they play.
R&D Sponsored 12 Questions With Marie Teil Marie Teil is a pharmaceutical executive with over 20 years of experience in the healthcare field. She leads UCB's Women of Childbearing Age programme
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
